6'-Guanidinonaltrindole
| Names | |
|---|---|
| IUPAC name
N-[17-(Cyclopropylmethyl)-3,14-dihydroxy-1′H-4,5α-epoxyindolo[2′,3′:6,7]morphinan-6′-yl]guanidine | |
| Systematic IUPAC name
N-[(4bS,8R,8aS,14bR)-7-(Cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methano[1]benzofuro[2,3-b]pyrido[4,3-c]carbazol-12-yl]guanidine | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
PubChem CID |
|
| |
| |
| Properties | |
| C27H29N5O3 | |
| Molar mass | 471.561 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
6′-Guanidinonaltrindole (6′-GNTI) is a κ–δ-opioid receptor selective ligand used in scientific research.
With 6′-GNTI, evidence was provided for the first time that receptor oligomerization plays functional role in living organisms.
6′-GNTI is an extremely biased agonist of the κ-opioid receptor. It is a potent partial agonist of the G protein pathway but does not recruit the β-arrestin pathway. Due to its functional selectivity for the G protein pathway, 6′-GNTI functions as an antagonist of nonbiased KOR agonists on the β-arrestin pathway. It is thought that 6′-GTNI may be able to produce analgesia without dysphoria and with a lower incidence of tolerance.